A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) von Woyach, Jennifer A., Ruppert, Amy S., Awan, Farrukh, Jones, Jeffrey A., Waymer, Sharon, Lozanski, Gerard, Muthusamy, Natarajan, Byrd, John C.

Volltext

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's... von Woyach, Jennifer A., Ruppert, Amy S., Awan, Farrukh T., Jones, Jeffrey, Andritsos, Leslie A., Waymer, Sharon, Lozanski, Gerard, Muthusamy, Natarajan, Byrd, John C.

Volltext

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia von Lin, Thomas S., Flinn, Ian W., Modali, Rama, Lehman, Teresa A., Webb, Jennifer, Waymer, Sharon, Moran, Mollie E., Lucas, Margaret S., Farag, Sherif S., Byrd, John C.

Volltext

Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) von Woyach, Jennifer Ann, Flynn, Joseph M., Jones, Jeffrey Alan, Andritsos, Leslie A., Lucas, Margaret, Chase, Weihong, Yang, Ying, Lucas, David M, Sass, Ellen, Waymer, Sharon, Ling, Yonghua, Jiang, Yao, Phelps, Mitch A., Byrd, John C.

Volltext